Group 1 - The core viewpoint of the article highlights that the National Health Commission has recognized orthokeratology lenses as an effective method for myopia prevention and control in its recently published guidelines [1] - The company's main product, orthokeratology lenses, is classified as a Class III medical device and has been in use for over 20 years, gaining recognition from both experts and users [1] - The number of users for the orthokeratology lenses has exceeded 2 million, indicating a strong market presence and acceptance [1]

Core Insights - The company participated in an online investor meeting on September 15, 2025, discussing business adjustments and new product developments [1][2]. Group 1: Business Adjustments - The decline in revenue from nursing products was attributed to the restructuring of online business and the cessation of partnerships with certain clients, leading to decreased distribution income [3]. - The company is exploring entry into the CPO, smart glasses, and brain-machine interface sectors through equity participation, having already established a partnership with Raytheon and Huiding for smart glasses, with the joint venture registered [3]. Group 2: New Products - Inquiries regarding the launch timeline for new products such as AI glasses and atropine eye drops were addressed, indicating that AI glasses are in preliminary preparation while atropine is still in phase III clinical trials, with disclosures to follow regulatory requirements [3]. - The company has launched scleral lenses in the first half of the year, aiming to capture a portion of the high-end frame market, although specific pricing strategies were not disclosed [3]. Group 3: Stock Repurchase - The company stated that any matters related to stock repurchase and cancellation would be disclosed in accordance with regulations, emphasizing that the meeting did not involve any undisclosed significant information [3].

Group 1: Financial Performance and Business Adjustments - The company's subsidiary adjusted its online business structure, leading to a decline in nursing product revenue due to the cessation of cooperation with certain clients [1] - The scleral lens was launched in the first half of the year, aiming to capture part of the high-end frame market [2] Group 2: Product Development and Future Plans - The joint venture with Thunder and Huiding has completed business registration, but products have not yet been officially launched [2] - The atropine eye drops are still in phase three clinical trials [2] Group 3: Strategic Initiatives and Market Positioning - The company is exploring acquisition or investment opportunities in high-tech firms producing CPO or smart glasses [1] - There is no public discussion on specific pricing strategies for scleral lenses, including potential reductions to 3900 yuan per pair [2] Group 4: Shareholder Engagement and Stock Management - Any stock repurchase plans will be disclosed according to regulations [2] - The activity did not involve any undisclosed significant information [2]

证券日报网讯欧普康视（300595）9月12日在互动平台回答投资者提问时表示，截至2025年9月10日，公 司股东总人数为61974户。 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-079 欧普康视科技股份有限公司 关于持股5%以上股东部分股份质押和解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）的通知，获悉其 将持有公司股份 226 万股质押给中信证券股份有限公司，并将前期质押给华龙证 券股份有限公司的 250 万股解除质押。现将具体情况公告如下： 一、股东股份质押及解除质押的基本情况 | 股东 | 是否为控 股股东或 | 本次质押数 | 占其 所持 | 占公 司总 | 是否 | 是否 为补 | 质押 | 质押 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 第一大股 | 量（股） | 股份 | 股本 | 为限 | 充质 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | | 比例 | 比例 | ...

Company Overview - Opcon Vision, established on October 26, 2000, and listed on January 17, 2017, is located in Hefei, Anhui Province. The company specializes in the research, production, and sales of optical products and related services [1][2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2]. - The company has distributed a total of 897 million yuan in dividends since its A-share listing, with 526 million yuan distributed over the past three years [3]. Stock Performance - As of September 11, Opcon Vision's stock price increased by 2.03% to 18.11 yuan per share, with a trading volume of 128 million yuan and a turnover rate of 1.07%, resulting in a total market capitalization of 16.229 billion yuan [1]. - Year-to-date, the stock price has decreased by 3.29%, with a 3.72% increase over the last five trading days, a 2.42% decrease over the last 20 days, and a 23.37% increase over the last 60 days [1]. Shareholder Structure - As of August 29, the number of shareholders for Opcon Vision was 61,700, a decrease of 3.70% from the previous period, with an average of 10,832 circulating shares per shareholder, an increase of 3.84% [2]. - The top ten circulating shareholders include significant institutional investors, with notable increases in holdings from various ETFs [3].

Core Viewpoint - The company reported that its online sales revenue for the first half of the year was approximately 30 million yuan [2] Group 1 - The company, 欧普康视, engaged with investors on September 10 through an interactive platform [2] - The reported online sales revenue reflects the company's performance in the e-commerce sector [2]

证券日报网讯欧普康视（300595）9月10日在互动平台回答投资者提问时表示，公司与雷神和汇鼎合资 的公司已完成工商注册，尚未正式推出相关产品。 ...

Core Viewpoint - The company has initiated production and sales of its products, primarily focusing on OEM orders, and has not yet launched its own brand [1] Group 1: Product and Sales Information - The company has started producing and selling its products, currently focusing on OEM orders and has not yet introduced its own brand [1] - The business performance of Shangyue Qicheng is reported to be good, with results aligning with commitments [1] - A joint venture with Raytheon and Huiding has been established, but the related products have not been officially launched yet, making it difficult to predict their impact on future performance [1]

Core Viewpoint - The company is steadily advancing its online channel development and has reported specific sales figures for both domestic and cross-border e-commerce [1] Group 1: Domestic E-commerce Development - The company's online channel construction is progressing steadily [1] - The online sales revenue for the parent company in the first half of the year is approximately 30 million [1] - The proportion of e-commerce sales in total revenue has not been specified but indicates a growing focus on this channel [1] Group 2: Cross-border E-commerce - The revenue from cross-border e-commerce is currently very small [1] - The company is in the process of promoting its cross-border e-commerce initiatives [1]